Page last updated: 2024-09-04

tipifarnib and letrozole

tipifarnib has been researched along with letrozole in 2 studies

Compound Research Comparison

Studies
(tipifarnib)
Trials
(tipifarnib)
Recent Studies (post-2010)
(tipifarnib)
Studies
(letrozole)
Trials
(letrozole)
Recent Studies (post-2010) (letrozole)
30992942,6126121,602

Protein Interaction Comparison

ProteinTaxonomytipifarnib (IC50)letrozole (IC50)
Steryl-sulfataseHomo sapiens (human)0.0009
AromataseHomo sapiens (human)0.009
Cytochrome P450 11B1, mitochondrialHomo sapiens (human)2.62
Cytochrome P450 11B2, mitochondrialHomo sapiens (human)1.42
Amine oxidase [flavin-containing] A Rattus norvegicus (Norway rat)0.0009

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (50.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bessems, A; De Porre, PM; Dodwell, DJ; Howes, AJ; Johnston, SR; Manikhas, GM; Neven, P; Park, YC; Perez Ruixo, JJ; Romieu, G; Semiglazov, VF; Spaeth, D; Wardley, AM1

Trials

1 trial(s) available for tipifarnib and letrozole

ArticleYear
A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy.
    Breast cancer research and treatment, 2008, Volume: 110, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Double-Blind Method; Estrogen Receptor Modulators; Farnesyltranstransferase; Female; Humans; Letrozole; Middle Aged; Nitriles; Quinolones; Time Factors; Treatment Outcome; Triazoles

2008

Other Studies

1 other study(ies) available for tipifarnib and letrozole

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013